Clinical trials: Rectal Neoplasm Malignant
Colorectal Neoplasms, Digestive System Diseases
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method.
- Conditions
- Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer
- Trial name
- DeeP-C (NCT01397747)
- Where
- 184 sites in United States, Canada
- Volunteers
- 12,776 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Colo-rectal Cancer
Plasma-based Colorectal Cancer Screening Research & Development
The objective of this Clinical Sample Collection Study is to develop a biobank of appropriately collected plasma samples from colorectal cancer patients (i.e.
- Trial name
- NCT04027790
- Testing
- Epi proColon
- Where
- 5 sites in United States
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Epigenomics, Inc
Colorectal Cancer Metastatic
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
This is a single center, open label dose frequency escalation study of CryoVax®. personalized anti-tumor vaccine protocol combining the cryoablation of a selected metastatic lesion with intra-lesional immunotherapy with…
- Trial name
- NCT02380443
- Testing
- AlloStim, Cryoablation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mirror Biologics, Inc.
Colorectal Cancer, Rectal Cancer
SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study
A randomized trial to assess the safety and effectiveness of the Colovac in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection for colorectal cancer.
- Conditions
- Colorectal Cancer, Rectal Cancer, Rectal Tumor, Rectal/Anal
- Trial name
- SAFE-2 (NCT05010850)
- Testing
- Colovac, Stoma Creation
- Where
- 16 sites in United States, Belgium and 1 more
- Volunteers
- 18 people
- Sponsor
- SafeHeal Inc
Colorectal Cancer, Colo-rectal Cancer
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01
The primary objective of this sub-study is to obtain de-identified, clinically characterized, stool specimens from subjects with untreated solid tumors for research use in the development and validation of a stool-based test for…
- Conditions
- Colorectal Cancer, Colo-rectal Cancer, Cancer
- Trial name
- NCT04473625
- Testing
- Stool Sample Collection
- Where
- 12 sites in United States
- Volunteers
- 291 people
- Sponsor
- Exact Sciences Corporation
Metastatic Colorectal Cancer
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
The primary objective of this study is to determine if panitumumab affects the pharmacokinetic (PK) profile of irinotecan.
- Trial name
- NCT00563316
- Testing
- Panitumumab, Irinotecan
- Where
- 12 sites in United States, Canada
- Volunteers
- 28 people
- Sponsor
- Amgen
Neoplasms, Colorectal, Solid Tumor
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat.
- Conditions
- Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer
- Trial name
- SYLVER (NCT06710847)
- Testing
- GSK4418959, PD-1 inhibitor
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Colorectal Neoplasms, Metastases
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
This is a phase II, multicenter, open-label study of cetuximab in patients with epidermal growth factor receptor (EGFR) negative, metastatic colorectal carcinoma who have progressed after receiving at least one standard…
- Conditions
- Colorectal Neoplasms, Metastases, Neoplasm
- Trial name
- NCT00083720
- Testing
- cetuximab
- Where
- 27 sites in United States, Canada
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Mid-low Locally Advanced Rectal Cancer
rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer
This is a multi-center, randomized, phase II study, aimed to evaluate the efficacy of investigational product at a dose of 1800 µg/day when given in combination with TNT.
- Trial name
- rSIFN-co (NCT07662278)
- Testing
- Recombinant Super-Compound Interferon (rSIFN-co), Total Neo-adjuvant therapy
- Volunteers
- 90 people
- Sponsor
- Sichuan Huiyang Life Science and Technology Corporation
Solid Tumor, Advanced Solid Tumor
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05737706
- Testing
- MRTX1133
- Where
- 14 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mirati Therapeutics Inc.
Prostate Cancer
MyProstateScore Equivalency With and Without DRE
The purpose of the study is to quantify the concordance of MPS results between first-catch urine samples collected post-DRE and those collected without a DRE.
- Trial name
- NCT05700370
- Testing
- MyProstateScore
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- LynxDx
Rectal Cancer, Colon Cancer
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with either FOLFIRI or FOLFOX4 chemotherapy regimens. This is a Phase 1b clinical study.
- Trial name
- NCT00101894
- Testing
- FOLFOX-4, AMG 706, Panitumumab (Part 1a only)
- Volunteers
- 119 people
- Sponsor
- Amgen
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection
- Conditions
- HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer
- Trial name
- NCT03677960
- Testing
- Topical ABI-1968 cream
- Where
- 2 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Antiva Biosciences
Metastatic Colorectal Cancer
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
This study evaluates the combination of SCO-101 to FOLFIRI for the treatment of metastatic colorectal cancer patients who have developed resistance to FOLFIRI treatment.
- Trial name
- NCT04247256
- Testing
- FOLFIRI Protocol, SCO-101
- Where
- 12 sites in Denmark, Germany and 1 more
- Volunteers
- 35 people
- Sponsor
- Scandion Oncology A/S